Med Fusion Named Roche Molecular Center of Excellence | GenomeWeb

NEW YORK (GenomeWeb News) – Roche today said that med fusion, a Lewisville, Texas-based clinical lab and clinical trials services firm, has been named a Roche Molecular Center of Excellence for the next five years.

As part of the designation, med fusion will offer a range of Roche's molecular technologies including the cobas 4800 V600 Mutation Test, a companion diagnostic approved by the US Food and Drug Administration last year for identifying patients who are eligible for treatment with the drug Zelboraf (vemurafenib) for inoperable or metastatic melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.